Tyra Biosciences (NASDAQ:TYRA) Price Target Cut to $30.00 by Analysts at HC Wainwright

Tyra Biosciences (NASDAQ:TYRA) had its target price trimmed by HC Wainwright from $32.00 to $30.00 in a research note released on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Tyra Biosciences’ Q4 2024 earnings at ($0.52) EPS, FY2024 earnings at ($1.59) EPS, Q1 2025 earnings at ($0.53) EPS, Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.56) EPS and FY2025 earnings at ($2.17) EPS.

Several other research analysts also recently weighed in on the stock. Piper Sandler assumed coverage on shares of Tyra Biosciences in a research note on Thursday, August 15th. They issued an “overweight” rating and a $33.00 target price for the company. Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and raised their target price for the company from $22.00 to $31.00 in a research note on Friday, October 18th. Oppenheimer raised their price target on shares of Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, September 19th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a report on Friday, October 25th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $31.00.

Tyra Biosciences Price Performance

Shares of TYRA opened at $16.34 on Monday. Tyra Biosciences has a 12 month low of $10.60 and a 12 month high of $29.60. The stock’s 50-day moving average is $21.51 and its two-hundred day moving average is $19.98. The stock has a market cap of $826.80 million, a PE ratio of -10.15 and a beta of 1.08.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.01). On average, research analysts anticipate that Tyra Biosciences will post -1.56 earnings per share for the current year.

Insider Activity

In other Tyra Biosciences news, CFO Alan Fuhrman purchased 9,500 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average cost of $16.00 per share, with a total value of $152,000.00. Following the acquisition, the chief financial officer now owns 12,849 shares of the company’s stock, valued at approximately $205,584. This represents a 283.67 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Nina S. Kjellson sold 27,493 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $16.56, for a total transaction of $455,284.08. Following the sale, the director now directly owns 458,506 shares of the company’s stock, valued at approximately $7,592,859.36. This represents a 5.66 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 101,050 shares of company stock worth $2,235,492. 15.40% of the stock is currently owned by insiders.

Institutional Trading of Tyra Biosciences

Several hedge funds have recently made changes to their positions in TYRA. Valence8 US LP bought a new position in Tyra Biosciences during the 3rd quarter worth $310,000. SG Americas Securities LLC acquired a new position in shares of Tyra Biosciences during the third quarter valued at $311,000. The Manufacturers Life Insurance Company bought a new position in shares of Tyra Biosciences during the third quarter worth about $333,000. HighVista Strategies LLC acquired a new stake in shares of Tyra Biosciences in the 2nd quarter worth about $257,000. Finally, Quest Partners LLC bought a new stake in Tyra Biosciences in the 3rd quarter valued at about $491,000. Institutional investors own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.